KR900004326A - 디히드로에르고톡신 및 그의 산 부가염의 분산성 정제 - Google Patents
디히드로에르고톡신 및 그의 산 부가염의 분산성 정제 Download PDFInfo
- Publication number
- KR900004326A KR900004326A KR1019890014160A KR890014160A KR900004326A KR 900004326 A KR900004326 A KR 900004326A KR 1019890014160 A KR1019890014160 A KR 1019890014160A KR 890014160 A KR890014160 A KR 890014160A KR 900004326 A KR900004326 A KR 900004326A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- addition salt
- acid addition
- dispersible tablet
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 양 조제의 투여 후 디히드로에르고톡신 메탄술포네이트의 혈장 농도의 평균값을 나타내는 그래프이다. A=4.5mg의 활성 물질을 함유하는 디히드로에르고톡신 메탄술포네이트의 분산성 정제. B=4.5mg의 디히드로에르고톡신 메탄술포네이트를 함유하는 경구용 정제 레더진.
Claims (6)
- 0.1 내지 4중량%의 디히드로에르고톡신 또는 그의 산 부가염, 4 내지 60중량%의 1종류이상의 봉해제, 0.8 내지 10중량%의 유기산 및, 임의로, 0.2 내지 2중량%의 항 산화제를 기타 통상의 보조제와 함께 함유함을 특징으로 하는 디히드로에르고톡신 또는 그의 산부가염의 분산성 정제.
- 제1항에 있어서, 디히드로에르고톡신의 메탄술포네이트 염을 함유함을 특징으로 하는 분산성 정제.
- 제1항에 있어서, 붕해제로서 전분 또는 변성 전분, 비세결정성 셀룰로스, 가교 결합된 카르복시메틸 셀롤로스 또는 폴리비닐 피롤리돈을 함유함을 특징으로 하는 분산성 정제.
- 제1항에 있어서, 유기 산으로서 시트르산, 타르타르산 말레산을 함유함을 특징으로 하는 분산성 정제.
- 제1항에 있어서, 항산화제로서 임의로 부틸히드록시아니솔을 함유함을 특징으로 하는 분산성 정제.
- 0.1 내지 4중량%의 디히드로에르고톡신 또는 그의 산 부가염, 4 내지 60중량%의 1종류 이상의 붕해제, 0.8 내지 10중량%의 유기산 및 임으뢰 0.2 내지 2중량%의 항산화제를 기타의 통상 보조제와 함께 과립화하고 이 과립을 압축하여 정제로 하는 것을 특징으로 하는 제1항 내지 제5항중 어느 한항에 따른 디히드로에르고톡신 또는 그의 산 부가염의 분산성 정제의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
YU01839/88A YU183988A (en) | 1988-09-30 | 1988-09-30 | Process for preparing dispersion pills of dihydroergotoxine |
YUP1839/88 | 1988-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR900004326A true KR900004326A (ko) | 1990-04-12 |
Family
ID=25555799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890014160A KR900004326A (ko) | 1988-09-30 | 1989-09-30 | 디히드로에르고톡신 및 그의 산 부가염의 분산성 정제 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5047247A (ko) |
EP (1) | EP0361354A1 (ko) |
JP (1) | JPH02129124A (ko) |
KR (1) | KR900004326A (ko) |
CA (1) | CA1335573C (ko) |
YU (1) | YU183988A (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629016A (en) * | 1991-01-30 | 1997-05-13 | Glaxo Wellcome Inc. | Water-dispersible tablets |
RU2106861C1 (ru) * | 1991-01-30 | 1998-03-20 | Дзе Веллкам Фаундейшн Лимитед | Диспергируемые в воде таблетки, способ их получения, гранулы и диспергирующий агент для получения таблеток |
IT1245890B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
US5523289A (en) * | 1991-04-15 | 1996-06-04 | Abbott Laboratories | Pharmaceutical composition |
GB9215908D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
GB9220667D0 (en) † | 1992-09-30 | 1992-11-11 | Unilever Plc | Improvements in or relating to dioic acids |
US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
FR2766089B1 (fr) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | Comprime multiparticulaire perfectionne a delitement rapide |
US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
GB2392446A (en) * | 2002-09-02 | 2004-03-03 | Reckitt Benckiser Nv | Resin comprising water-soluble polymer and water-soluble filler |
GB0223978D0 (en) * | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
US20100016322A1 (en) * | 2007-02-28 | 2010-01-21 | Nagesh Nagaraju | Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same |
WO2011081118A1 (ja) * | 2009-12-29 | 2011-07-07 | 興和株式会社 | 経口投与用医薬組成物 |
WO2011081117A1 (ja) * | 2009-12-29 | 2011-07-07 | 興和株式会社 | 経口投与用固形医薬組成物 |
EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
AU2015283133B2 (en) | 2014-07-02 | 2019-05-16 | ObsEva SA | Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR5468M (ko) * | 1966-06-24 | 1967-10-16 | ||
JPS5332126A (en) * | 1976-09-02 | 1978-03-27 | Sandoz Ag | Improvement in organic compound |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
-
1988
- 1988-09-30 YU YU01839/88A patent/YU183988A/xx unknown
-
1989
- 1989-09-25 EP EP89117650A patent/EP0361354A1/en not_active Withdrawn
- 1989-09-26 CA CA000613266A patent/CA1335573C/en not_active Expired - Fee Related
- 1989-09-26 US US07/412,740 patent/US5047247A/en not_active Expired - Fee Related
- 1989-09-29 JP JP1252538A patent/JPH02129124A/ja active Pending
- 1989-09-30 KR KR1019890014160A patent/KR900004326A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US5047247A (en) | 1991-09-10 |
CA1335573C (en) | 1995-05-16 |
JPH02129124A (ja) | 1990-05-17 |
YU183988A (en) | 1990-08-31 |
EP0361354A1 (en) | 1990-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900004326A (ko) | 디히드로에르고톡신 및 그의 산 부가염의 분산성 정제 | |
CA2258095A1 (en) | Tetrahydrolipstatin containing compositions | |
ATE100708T1 (de) | Unbeschichtete pharmazeutische reaktionstablette. | |
KR950007841A (ko) | 트라마돌 염을 함유하는 서방성 약물 제제 | |
NZ336789A (en) | Use of methacrylic acid copolymer type C in the manufacture of tablets | |
RU93036959A (ru) | Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства | |
AU2793989A (en) | Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained | |
RU2003100507A (ru) | Фармацевтические композиции | |
SK282506B6 (sk) | Tableta obsahujúca paracetamol a domperidon | |
HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
IE64850B1 (en) | Therapeutically active substituted benzimidazole and process for its preparation | |
SE8901003L (sv) | Snabbloesliga preparat | |
ATE441410T1 (de) | Fenofibrattabletten | |
HU901095D0 (en) | Process for producing compound reducing extraction of gastric acid and pharmaceutical preparative containing said compound | |
HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
BE2016C017I2 (ko) | ||
GB2061111A (en) | Long acting pharmaceutical composition | |
EA200101108A1 (ru) | Полиморфные модификации кристаллического цитрата азабицикло[2.2.2]октан-3-амина и их фармацевтические композиции | |
KR20030076051A (ko) | 실데나필 젖산염의 속효제형 | |
JP2004043509A (ja) | プラバスタチンナトリウム錠の貯蔵安定化方法 | |
DK0483320T3 (da) | Farmaceutiske sammensætninger med forlænget frigivelse til peroral indgivelse og fremgangsmåde til fremstilling deraf | |
UA80270C2 (en) | Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid | |
EP0367509A3 (en) | Formulations | |
DE60024439D1 (de) | Enalaprilmaleat enthaltende, stabile, feste arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |